Literature DB >> 20818338

miRNA expression profiling of lung adenocarcinomas: correlation with mutational status.

Sanja Dacic1, Lindsey Kelly, Yongli Shuai, Marina N Nikiforova.   

Abstract

MicroRNA (miRNA) expression is deregulated in lung cancer, and some miRNAs are associated with poor prognosis and survival. In this study, we investigated the miRNA expression in lung adenocarcinomas with different oncogenic mutations, including EGFR-positive, KRAS-positive and EGFR/KRAS-negative tumors. The expression of 319 miRNAs was evaluated by Exiqon/Luminex microarray, and expression of individual miRNAs was validated by individual RT-PCR assays (Applied Biosystems). Overall, miRNA expression was similar among three mutationally different groups with most upregulated miRNAs being miR-20a, miR-328, miR-34c and miR-18b and most downregulated miRNAs being miR-32, miR-137 and miR-342. Four miRNAs (miR-155, miR-25, miR-495 and miR-7g) were expressed differently among these tumors. miR-155 was upregulated only in EGFR/KRAS-negative group, miR-25 was upregulated only in EGFR-positive group and miR-495 was upregulated only in KRAS-positive adenocarcinomas. In opposite, let-7g was downregulated in all three groups, with more significant downregulation in EGFR/KRAS-negative adenocarcinomas. Principal component analysis (PCA) revealed significant correlation between miRNA expression patterns and somatic mutations. In this study, we demonstrated that despite the similarity in miRNA expression among lung adenocarcinomas with different somatic mutations, some miRNAs showed unique expression patterns, which were in strong correlation with the mutation type, suggesting different carcinogenic pathway for these tumors. These miRNAs can be further explored for their diagnostic and prognostic use.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20818338     DOI: 10.1038/modpathol.2010.152

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  75 in total

1.  miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma.

Authors:  Nataliya Razumilava; Steve F Bronk; Rory L Smoot; Christian D Fingas; Nathan W Werneburg; Lewis R Roberts; Justin L Mott
Journal:  Hepatology       Date:  2011-12-19       Impact factor: 17.425

2.  miR-342-3p targets RAP2B to suppress proliferation and invasion of non-small cell lung cancer cells.

Authors:  Xiao Xie; Hongtao Liu; Mingsong Wang; Fangbao Ding; Haibo Xiao; Fengqing Hu; Rui Hu; Ju Mei
Journal:  Tumour Biol       Date:  2015-02-09

3.  Circulating miRNAs is a potential marker for gefitinib sensitivity and correlation with EGFR mutational status in human lung cancers.

Authors:  Qiang Zhao; Jun Cao; Yi-Chen Wu; Xiang Liu; Jing Han; Xian-Cong Huang; Lie-Hao Jiang; Xiu-Xiu Hou; Wei-Min Mao; Zhi-Qiang Ling
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

4.  miR-137 Targets p160 Steroid Receptor Coactivators SRC1, SRC2, and SRC3 and Inhibits Cell Proliferation.

Authors:  Vijay Kumar Eedunuri; Kimal Rajapakshe; Warren Fiskus; Chuandong Geng; Sue Anne Chew; Christopher Foley; Shrijal S Shah; John Shou; Junaith S Mohamed; Cristian Coarfa; Bert W O'Malley; Nicholas Mitsiades
Journal:  Mol Endocrinol       Date:  2015-06-12

Review 5.  Superficial spreading and nodular melanoma are distinct biological entities: a challenge to the linear progression model.

Authors:  Holly S Greenwald; Erica B Friedman; Iman Osman
Journal:  Melanoma Res       Date:  2012-02       Impact factor: 3.599

Review 6.  The microRNAs within the DLK1-DIO3 genomic region: involvement in disease pathogenesis.

Authors:  Leonidas Benetatos; Eleftheria Hatzimichael; Eric Londin; George Vartholomatos; Phillipe Loher; Isidore Rigoutsos; Evangelos Briasoulis
Journal:  Cell Mol Life Sci       Date:  2012-07-24       Impact factor: 9.261

7.  Bioinformatic and metabolomic analysis reveals miR-155 regulates thiamine level in breast cancer.

Authors:  Sinae Kim; Je-keun Rhee; Hyun Ju Yoo; Hee Jin Lee; Eun Ji Lee; Jong Won Lee; Jong Han Yu; Byung Ho Son; Gyungyup Gong; Sung Bae Kim; Shree Ram Singh; Sei Hyun Ahn; Suhwan Chang
Journal:  Cancer Lett       Date:  2014-12-04       Impact factor: 8.679

8.  MicroRNA gene dosage alterations and drug response in lung cancer.

Authors:  Katey S S Enfield; Greg L Stewart; Larissa A Pikor; Carlos E Alvarez; Stephen Lam; Wan L Lam; Raj Chari
Journal:  J Biomed Biotechnol       Date:  2011-03-31

9.  The expression of miR-25 is increased in colorectal cancer and is associated with patient prognosis.

Authors:  Xiaojun Li; Chunyan Yang; Xiaoqiang Wang; Jian Zhang; Ruipeng Zhang; Ruiting Liu
Journal:  Med Oncol       Date:  2013-11-29       Impact factor: 3.064

10.  Independent validation test of the vote-counting strategy used to rank biomarkers from published studies.

Authors:  Brad A Rikke; Murry W Wynes; Leslie M Rozeboom; Anna E Barón; Fred R Hirsch
Journal:  Biomark Med       Date:  2015-07-30       Impact factor: 2.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.